​​

Psychedelic-assisted therapy is an emerging field in mental health that combines psychotherapy with substances that can temporarily change perception, emotion, and cognition. Research suggests that, when used in structured clinical settings, these treatments may help individuals access difficult emotions, shift rigid thinking patterns, and process trauma or addiction in new ways.

Unlike recreational drug use, psychedelic-assisted therapy takes place in a controlled therapeutic environment with trained clinicians and a clear treatment framework.

Today, several psychedelic-based therapies are being studied for conditions such as depression, PTSD, substance use disorders, and end-of-life distress.

 

What is Psychedelic Therapy?

Psychedelic-assisted therapy is a treatment approach where specific medications are combined with psychotherapy to support emotional processing and psychological insight.

These substances affect brain networks involved in mood, perception, and emotional memory. Many patients report that these experiences allow them to view long-standing problems from a different perspective.

Research suggests psychedelics may temporarily reduce rigid patterns of thinking and increase psychological flexibility, which can support therapeutic change.

 

Common substances studied in psychedelic therapy include:

• Ketamine
• Psilocybin
• MDMA
• LSD (in research settings)

 

Some of these treatments are already legally available in medical settings, while others are still in clinical trials.

 

The History of Psychedelic Therapy

Psychedelic therapy research began in the 1950s and 1960s, when scientists studied substances like LSD and psilocybin for depression, alcoholism, and end-of-life anxiety.

During this period, more than 1,000 clinical papers and over 40,000 patient treatments were reported.

In the early 1970s, psychedelic research largely stopped due to regulatory changes and cultural concerns about recreational drug use.

Interest in psychedelic therapy began to return in the 1990s, when researchers restarted carefully controlled clinical trials.

Today, universities such as Johns Hopkins, NYU, UCLA, and Imperial College London are leading new research programs studying psychedelic-assisted therapy.

 

How Psychedelic Therapy Works

Modern neuroscience suggests psychedelics influence several important brain systems involved in mood and emotional regulation.

​

Research shows these substances may:

• Increase neuroplasticity, helping the brain form new connections
• Temporarily reduce activity in the default mode network, a system linked to rumination and rigid thinking
• Enhance emotional processing and memory reconsolidation
• Increase feelings of connection and meaning

 

In therapy, these effects may help patients access emotions or insights that are difficult to reach through traditional talk therapy alone.

Psychotherapy remains a key part of the treatment process, helping individuals prepare for the experience and integrate insights afterward.

 

The Therapeutic Use of Hallucinogens

Researchers are currently studying psychedelic therapies for several mental health conditions.

Areas of research include:

​

• Treatment-Resistant Depression
• Post-Traumatic Stress Disorder (PTSD)
• Alcohol Use Disorder
• Smoking Cessation
• End-of-Life Anxiety
• Obsessive Compulsive Disorder

 

Many of these studies have shown promising results, particularly for individuals who have not responded to traditional treatments.

However, these treatments are not appropriate for everyone and require careful screening and professional supervision.

 

Psychedelic Drug Therapy Research and Legal Status

Different psychedelic treatments are currently at different stages of research and legal availability.

 

 

Ketamine-Assisted Therapy (KAT)

​

Ketamine is currently the only psychedelic-related medication legally used in clinical mental health treatment in the United States.

It has been used safely in medicine as an anesthetic since the 1970s.

 

Over the past two decades, research has shown ketamine can rapidly reduce symptoms of:

• Treatment-Resistant Depression
• Suicidal Ideation
• PTSD
• Certain chronic pain conditions

 

Many clinics now offer Ketamine-Assisted Therapy (KAT) under medical supervision.

Learn more about Ketamine-Assisted Therapy →

 

 

Psilocybin-Assisted Therapy (PAT)

​

Psilocybin is the active compound found in certain species of mushrooms.

​

Clinical trials have shown promising results for:

• Major Depressive Disorder
• Treatment-Resistant Depression
• Alcohol Use Disorder
• End-of-Life Anxiety

 

Large Phase 2 and Phase 3 trials are currently underway.

Many experts believe psilocybin-assisted therapy may receive FDA approval for depression as early as 2026, pending regulatory review.

Learn more about Psilocybin-Assisted Therapy →
 

​

Psychedelics for Therapy: Clinical Considerations

While psychedelic therapies show promising results, they also require careful clinical consideration.

Important factors include:

​

• Proper medical and psychological screening
• Presence of trained clinicians during treatment
• Integration therapy after the experience
• Monitoring for individuals with risk factors such as psychotic disorders

​

 

Current Evidence Snapshot

​

Ketamine-Assisted Therapy (KAT)
Research suggests:

• 50–70% of patients with treatment-resistant depression show meaningful symptom improvement
• Rapid reduction in suicidal ideation can occur within hours in some cases
• Effects may last days to weeks after a single treatment

 

Psilocybin-Assisted Therapy (PAT)
Clinical trials suggest:

• Around 60–70% of patients with treatment-resistant depression show significant improvement
• Many patients maintain improvement for several months after treatment
• Early studies show reductions in alcohol misuse and smoking addiction

Research is ongoing, and results continue to evolve as larger clinical trials are completed.

 

The Future of Psychedelic Therapy

Psychedelic-assisted therapy is one of the fastest-growing areas of research in mental health.

Major universities, hospitals, and research institutes are currently studying how these treatments may help individuals who have not responded to conventional care.

​

Possible developments in the coming years include:

• FDA approval of psilocybin therapy for depression
• Expanded clinical guidelines for psychedelic-assisted psychotherapy
• Increased training programs for mental health professionals
• Greater understanding of how these therapies support long-term healing

 

As research continues, psychedelic-assisted therapy may become an important addition to the tools available for treating complex mental health conditions.

​